Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.
作者信息
Heikamp Emily B, Pui Ching-Hon
机构信息
Department of Pediatrics, Section of Pediatric Hematology-Oncology, Baylor College of Medicine, Houston, TX; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, TX.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN; Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN.
出版信息
J Pediatr. 2018 Dec;203:14-24.e2. doi: 10.1016/j.jpeds.2018.07.039. Epub 2018 Sep 10.
Abstract
摘要
相似文献
1
Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.
J Pediatr. 2018 Dec;203:14-24.e2. doi: 10.1016/j.jpeds.2018.07.039. Epub 2018 Sep 10.
2
Next-Generation Sequencing in Acute Lymphoblastic Leukemia.
Int J Mol Sci. 2019 Jun 15;20(12):2929. doi: 10.3390/ijms20122929.
3
Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
Leuk Lymphoma. 2019 Nov;60(11):2838-2840. doi: 10.1080/10428194.2019.1607325. Epub 2019 May 3.
4
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
Semin Cancer Biol. 2022 Sep;84:144-152. doi: 10.1016/j.semcancer.2020.10.013. Epub 2020 Nov 13.
5
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
Leukemia. 2016 Jul;30(7):1615-9. doi: 10.1038/leu.2016.17. Epub 2016 Feb 12.
6
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?
Expert Rev Hematol. 2024 Jun;17(6):189-191. doi: 10.1080/17474086.2024.2354922. Epub 2024 May 14.
7
Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.
JAMA Oncol. 2016 Jan;2(1):132-3. doi: 10.1001/jamaoncol.2015.3788.
8
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
BMC Cancer. 2020 Jun 30;20(1):612. doi: 10.1186/s12885-020-07077-9.
9
Personalized medicine in adult acute lymphoblastic leukemia.
Haematologica. 2015 Jul;100(7):855-8. doi: 10.3324/haematol.2015.127837.
10
Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
Ann Hematol. 2019 Mar;98(3):657-668. doi: 10.1007/s00277-018-3554-8. Epub 2018 Nov 17.
引用本文的文献
1
A Comprehensive Review of Somatic and Germline Biomarkers Associated with Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: From Biological Significance to Precision Medicine Opportunities.
Biomedicines. 2025 Jul 2;13(7):1626. doi: 10.3390/biomedicines13071626.
2
[Diagnosis and treatment of pediatric acute lymphoblastic leukemia: Historical review].
Rev Med Inst Mex Seguro Soc. 2025 Jul 1;63(4):e6552. doi: 10.5281/zenodo.15644329.
3
Global, regional, and national burdens of leukemia from 1990 to 2019: A systematic analysis of the global burden of disease in 2019 based on the APC model.
Cancer Med. 2024 Sep;13(17):e7150. doi: 10.1002/cam4.7150.
4
[Not Available].
Cancer Rep (Hoboken). 2024 Aug;7(8):e2162. doi: 10.1002/cnr2.2162.
5
[Clinical characteristics and prognosis of childhood acute lymphoblastic leukemia with CD123 expression].
Zhongguo Dang Dai Er Ke Za Zhi. 2024 Jul 15;26(7):708-715. doi: 10.7499/j.issn.1008-8830.2312152.
6
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
EClinicalMedicine. 2023 Oct 26;65:102268. doi: 10.1016/j.eclinm.2023.102268. eCollection 2023 Nov.
7
Drivers of Differential Time to Diagnosis in Pediatric ALL Tied to Race and Ethnicity.
J Pediatr Hematol Oncol. 2023 Oct 1;45(7):e879-e884. doi: 10.1097/MPH.0000000000002720. Epub 2023 Jul 26.
8
Impact of race/ethnicity and language preferences on pediatric ALL survival outcomes.
Cancer Med. 2023 Jun;12(11):12827-12836. doi: 10.1002/cam4.5951. Epub 2023 Apr 16.
9
Go with the Flow-Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009.
Cancers (Basel). 2022 Oct 30;14(21):5359. doi: 10.3390/cancers14215359.
10
Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice.
Front Pediatr. 2022 Sep 12;10:980234. doi: 10.3389/fped.2022.980234. eCollection 2022.
本文引用的文献
1
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol. 2020 Oct 1;38(28):3282-3293. doi: 10.1200/JCO.20.00256. Epub 2020 Aug 19.
2
Global efforts toward the cure of childhood acute lymphoblastic leukaemia.
Lancet Child Adolesc Health. 2018 Jun;2(6):440-454. doi: 10.1016/S2352-4642(18)30066-X. Epub 2018 Mar 30.
3
Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.
Cancer Cell. 2018 May 14;33(5):937-948.e8. doi: 10.1016/j.ccell.2018.03.021. Epub 2018 Apr 19.
4
IKZF1 Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.
5
TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.
J Clin Oncol. 2018 Feb 20;36(6):591-599. doi: 10.1200/JCO.2017.75.5215. Epub 2018 Jan 4.
6
Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.
Blood. 2018 Mar 22;131(12):1350-1359. doi: 10.1182/blood-2017-09-806521. Epub 2017 Dec 28.
7
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.
8
Redirecting T cells to hematological malignancies with bispecific antibodies.
Blood. 2018 Jan 4;131(1):30-38. doi: 10.1182/blood-2017-06-741058. Epub 2017 Nov 8.
9
Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.
Blood. 2018 Jan 18;131(3):289-300. doi: 10.1182/blood-2017-04-778829. Epub 2017 Oct 19.
10
Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):464-470. doi: 10.1016/j.clml.2017.03.299.
Zotero 插件